RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Sees Large Decline in Short Interest

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 338 shares, a decline of 82.9% from the June 15th total of 1,978 shares. Based on an average daily trading volume, of 503 shares, the short-interest ratio is presently 0.7 days. Currently, 0.0% of the company’s stock are sold short.

RCN Pareto Strategic Allocation ETF Price Performance

Shares of NYSEARCA:PRTO traded down $0.04 during midday trading on Friday, hitting $27.58. 407 shares of the company’s stock were exchanged. RCN Pareto Strategic Allocation ETF has a 12 month low of $24.68 and a 12 month high of $28.16. The company has a market cap of $611.70 million, a PE ratio of -28.73 and a beta of 0.60.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.